2,914
Views
42
CrossRef citations to date
0
Altmetric
Research Articles

Drug Interactions between Common Illicit Drugs and Prescription Therapies

, Pharm.D., , Pharm.D. & , Pharm.D.
Pages 334-343 | Published online: 05 Jan 2012

REFERENCES

  • Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings. Rockville, MD: Office of Applied Studies, 2010.
  • Baxter K, ed. Stockley’s Drug Interactions. (7th ed.). Chicago, IL: Pharmaceutical Press, 2006.
  • Lacy C, ed. Lexi-Comp’s Drug Information: Drug Information Handbook. (18th ed.). Hudson, OH: Lexi-Comp, 2010.
  • Micromedex® Healthcare Series. Thomson Reuters (Healthcare) Inc., Greenwood Village, CO. Available at http://www.thomsonhc.com. Last accessed on March 29, 2011.
  • Dean A. Illicit drugs and drug interactions. Australian Pharm 2006; 25(9):684–689.
  • Teens and Prescription Drugs: An Analysis of Recent Trends on the Emerging Drug Threat. Washington, DC: Office of National Drug Control Policy, 2007.
  • Horn JR, Hansten PD. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41:674–680.
  • Jasinski DR, Preston KL. Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects. Drug Alcohol Depend 1986; 17:1–13.
  • Krystal JH, Perry EB, Gueorguieva R, Belger A, Modonick SH, Abi-Dargham A, Cooper TB, MacDougall L, Abi-Saab W, D‘Souza DC. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine. Arch Gen Psychiatry 2005; 62:985–995.
  • Mintzer MZ, Griffiths RR. Triazolam-amphetamine interaction: dissociation of effects on memory versus arousal. J Psychopharmacol 2003; 17:17–29.
  • Whitley H, Moorman K. Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine. Pharmacotherapy 2007; 27(10):1440–1445.
  • Vuori E, Henry JA, Ojanpera I, Nieminen R, Savolainen T, Wahlsten P, Jantti M. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 2003; 98:365–368.
  • Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998; 352:1751–1752.
  • Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizk PS, Abrams DI. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002; 16:543–550.
  • Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, Bedotto JB, Danzinger RS, Hillis LD. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990; 112:897–903.
  • McCance-Katz EF, Kosten TR, Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend 1998; 52:27–39.
  • McCance-Katz EF, Jatlow P, Rainey PM. Effect of Cocaine use on methadone pharmacokinetics in Humans. Am J Addict 2010; 19(1):47–52.
  • Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999; 159:2221–2224.
  • Barr AM, Panenka WJ, MacEwan GW, Thorton AE, Lang DJ, Honer WG, Lecomte T. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006; 31(5):301–313.
  • Lin L, Di Stefano E, Schmitz D, Hsu L, Ellis SW, Lennard MS, Tucker GT, Cho AK. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos 1997; 25:1059–1064.
  • Lin L, Kumagai Y, Hiratsuka A, Narimatsu S, Suzuki T, Funae Y, DiStefano EW, Cho AK. Cytochrome P4502D isozymes catalyze the 4-hydroxylation of methamphetamine enantiomers. Drug Metab Dispos 1995; 29:100–102.
  • Johnson BA, Wells LT, Roache JD, Wallace C, Ait-Daoud N, Wang Y. Isradipine decreases the hemodynamic response of cocaine and methamphetamine. Am J Hypertens 2005; 18:813–822.
  • Johnson BA, Roache JD, Bordnick PS, Narimatsu S, Suzuki T, Funae Y, DiStefano EW, Cho AK. Isradipine, a dihydropyridine-class calcium channel antogonist, attenuates some of d-methamphetamine’s positive subjective effects: a preliminary study. Psychopharmacology 1999; 144:295–300.
  • Stephens LC, Katz SG. Phentermine and analgesia. Anaesth Intensive Care 2005; 33:525–527.
  • White P, Way W, Trevor AJ. Ketamine – its pharmacology and therapeutic uses. Anesthesiology 1982; 56:119–136.
  • Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, Iga T. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001; 29:887–890.
  • Oesterheld JR, Armstrong SC, Cozza KL. Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics 2004; 45:84–87.
  • Hrometz SL, Brown AW, Nichols DE, Sprague JE. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B. Neurosci Lett 2004; 367:56–59.
  • Bonnet U. Meclobemide: evolution, pharmacodynamic, and pharmacokinetic properties. CNS Drug Rev 2002; 8(3):283–308.
  • Hales G, Roth N, Smith D. Possible fatal interaction between protease inhibitors and methamphetamine. Antivir Ther 2000; 5(1):19.
  • National Institute on Drug Abuse [homepage on the internet]. Bethesda, MD. Available at http://www.nida.nih.gov/DrugPages/Marijuana.html. Last accessed on April 21, 2011.
  • Sala M, Braida D. Endocannabinoids and 3,4-methylenedioxymethamphetamine (MDMA) interaction. Pharmacol Biochem Behav 2005; 81:407–416.
  • Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 2005; 70:1096–1103.
  • Stoll AL, Cole JO, Lukas SE. A case of mania as a result of fluoxetine-marijuana interaction. J Clin Psychiatry 1991; 52(6):280–281.
  • Wilens TE, Biederman J, Spencer TJ. Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 1997; 36:45–48.
  • McLeod AL, McKenna CJ, Northridge DB. Myocardial infarction following the combined recreational use of Viagra and cannabis. Clin Cardiol 2002; 25(3):133–134.
  • Yamreudeewong W, Wong HK, Brausch LM, Pulley KR. Probable interaction between warfarin and marijuana smoking. Ann Pharmacother 2009; 43(7):1347–1353.
  • Kozak P. Factors that influence theophylline metabolism. West J Med 1979; 131:319–320.
  • Russmann S, Winkler A, Lovblad KO, Stanga Z, Bassetti C. Lethal ischemic stroke after cisplatin-based chemotherapy for testicular carcinoma and cannabis inhalation. Eur Neurol 2002; 48(3):178–180.
  • Liappas IA, Malitas PN, Dimopoulos NP, Gista OE. A zolpidem and cocaine abuse case report. Int J Psychiatry Clin Practice 2002; 6(4):217–219.
  • Haberny KA, Walsh SL, Ginn DH, Wilkins JN, Garner JE, Setoda D, Bigelow GE. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend 1995; 39:55–62.
  • Shih RD, Hollander JE, Burstein JL, Nelson LS, Hoffman RS, Quick AM. Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction. Ann Emerg Med 1995; 26:702–706.
  • United States Drug Enforcement Administration. Drugs of abuse. Department of Justice. 2005. Available at http://www.justice.gov/dea/pubs/abuse/doa-p.pdf. Last accessed on January 22, 2007.
  • Schlicker E, Gothert M. Interactions between the presynaptic alpha2-autoreceptor and presynaptic inhibitory heteroreceptors on noradrenergic neurones. Brain Res Bull 1998; 47(2):129–132.
  • Backmund M, Meyer K, Henkel C, Soyka M, Reimer J, Schutz CG. Co-consumption of benzodiazepines in heroin users, methadone-substituted and codeine-substituted patients. J Addict Dis 2005; 24(4):17–29.
  • Walker BM, Ettenberg A. The effects of alprazolam on conditioned place preferences produced by intravenous heroin. Pharmacol Biochem Behav 2003; 75:75–80.
  • Thai D, Dyer JE, Benowitz NL, Haller CA. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol 2006; 26(5):524–529.
  • Martindale: The Complete Drug Reference. Pharmaceutical Press. Electronic version, Thomson Micromedex. Available at http://www.thomsonhc.com. Last accessed on November 21, 2006.
  • Lemon MD, Strain JD, Farver DK. Sodium oxybate for cataplexy. Ann Pharmacother 2006; 40(3):433–440.
  • O’Connell T, Kaye L, Plosay JJ, 3rd. Gamma-hydroxybutyrate (GHB): a newer drug of abuse. Am Fam Physician 2000; 62:2478–2483.
  • Pulido JN, Mantilla CB. Sodium oxybate (gamma-hydroxybutyrate): anesthetic agent or source of anesthetic interactions? Mayo Clin Proc 2005; 80:960.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.